Cigna Files 8-K on Feb 7 for Feb 5 Event; Details Pending

TL;DR

**Cigna filed an 8-K, signaling an upcoming disclosure; stay tuned for details.**

AI Summary

The Cigna Group filed an 8-K on February 7, 2024, reporting an event that occurred on February 5, 2024. This filing is categorized under "Other Events" and "Financial Statements and Exhibits." While the specific details of the event are not provided in this summary, the filing indicates that Cigna, a major health services company, is updating its public record. This matters to investors because 8-K filings often precede significant announcements, and shareholders should monitor for further details that could impact the company's financial health or strategic direction.

Why It Matters

This 8-K signals that Cigna has an important event to disclose, and investors should watch for subsequent filings or announcements to understand the full implications for the company's stock.

Risk Assessment

Risk Level: medium — The risk is medium because an 8-K for 'Other Events' without immediate detail creates uncertainty, which could be positive or negative for the stock.

Analyst Insight

A smart investor would add Cigna to their watchlist and set up alerts for any subsequent filings or press releases that provide details on the 'Other Event' mentioned in this 8-K, as this could significantly impact the stock price.

Key Numbers

• 001-38769 — Commission File Number (identifies Cigna's filings with the SEC)
• 82-4991898 — IRS Employer Identification No. (Cigna's tax identification number)
• 2024-02-05 — Date of earliest event reported (the date the event being reported in the 8-K occurred)
• 2024-02-07 — Date of Report (the date the 8-K was filed with the SEC)

Key Players & Entities

• The Cigna Group (company) — registrant filing the 8-K
• Delaware (company) — state of incorporation for The Cigna Group
• New York Stock Exchange, Inc. (company) — exchange where Cigna's Common Stock is registered
• $0.01 (dollar_amount) — par value of Cigna's Common Stock

Forward-Looking Statements

• Cigna will release further details about the 'Other Event' reported in this 8-K. (The Cigna Group) — high confidence, target: 2024-02-14

FAQ

Key Financial Figures

• $0.01 — ich registered Common Stock, Par Value $0.01 CI New York Stock Exchange, Inc.
• $1 billion — the issuance and sale by the Company of $1 billion in aggregate principal amount of its 5.
• $750 million — nior Notes due 2029 (the "2029 Notes"), $750 million in aggregate principal amount of its 5.
• $1.25 billion — nior Notes due 2031 (the "2031 Notes"), $1.25 billion in aggregate principal amount of its 5.
• $1.5 billion — r Notes due 2034 (the "2034 Notes") and $1.5 billion in aggregate principal amount of its 5.
• $2.25 billion — offers (the "Tender Offers") for up to $2.25 billion in aggregate principal amount of outsta

Filing Documents

• ny20020170x2_8k.htm (8-K) — 24KB
• ny20020170x2_ex1-1.htm (EX-1.1) — 240KB
• 0001140361-24-005982.txt ( ) — 436KB
• ci-20240205.xsd (EX-101.SCH) — 4KB
• ci-20240205_lab.xml (EX-101.LAB) — 22KB
• ci-20240205_pre.xml (EX-101.PRE) — 16KB
• ny20020170x2_8k_htm.xml (XML) — 4KB

01

Item 8.01 Other Events. On February 5, 2024, The Cigna Group (the "Company") entered into an Underwriting Agreement (the "Underwriting Agreement") with Deutsche Bank Securities Inc., Goldman Sachs & Co. LLC, J.P. Morgan Securities LLC and Wells Fargo Securities, LLC, as representatives of the underwriters named in Schedule I thereto, with respect to the issuance and sale by the Company of $1 billion in aggregate principal amount of its 5.000% Senior Notes due 2029 (the "2029 Notes"), $750 million in aggregate principal amount of its 5.125% Senior Notes due 2031 (the "2031 Notes"), $1.25 billion in aggregate principal amount of its 5.250% Senior Notes due 2034 (the "2034 Notes") and $1.5 billion in aggregate principal amount of its 5.600% Senior Notes due 2054 (together with the 2029 Notes, the 2031 Notes and the 2034 Notes, the "Notes"). The Notes are being offered and sold pursuant to the Company's shelf registration statement on Form S-3ASR (File No. 333-268633). The Company intends to use the proceeds to pay the consideration for the announced tender offers (the "Tender Offers") for up to $2.25 billion in aggregate principal amount of outstanding notes with maturities in 2024, 2025, 2026, 2027 and 2030. The Company intends to use the remaining proceeds not applied to the Tender Offers to fund the repayment of its 0.613% Senior Notes due 2024 at maturity and for general corporate purposes, which may include repayment of indebtedness and repurchases of shares of its common stock. The Underwriting Agreement contains customary representations, warranties and agreements of the Company, conditions to closing, indemnification rights and obligations of the parties, and termination provisions. The foregoing description of the Underwriting Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Underwriting Agreement, which is filed as Exhibit 1.1 hereto and incorporated by reference herein.

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 1.1 Underwriting Agreement, dated as of February 5, 2024, by and among The Cigna Group and Deutsche Bank Securities Inc., Goldman Sachs & Co. LLC, J.P. Morgan Securities LLC and Wells Fargo Securities, LLC, as representatives of the underwriters named therein. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. THE CIGNA GROUP Date: February 7, 2024 By: /s/ Brian C. Evanko Brian C. Evanko Executive Vice President and Chief Financial Officer and President and Chief Executive Officer, Cigna Healthcare

View Full Filing

View this 8-K filing on SEC EDGAR